Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 8.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 848,630 shares of the company’s stock after selling 83,020 shares during the quarter. American Century Companies Inc. owned 1.71% of Mineralys Therapeutics worth $10,447,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Polar Asset Management Partners Inc. acquired a new position in shares of Mineralys Therapeutics during the third quarter valued at $490,000. Jennison Associates LLC increased its stake in Mineralys Therapeutics by 55.4% during the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company’s stock valued at $13,319,000 after buying an additional 385,726 shares during the period. Barclays PLC raised its position in shares of Mineralys Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 38,218 shares of the company’s stock worth $463,000 after buying an additional 28,208 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Mineralys Therapeutics in the 3rd quarter worth approximately $775,000. Finally, Proficio Capital Partners LLC bought a new position in shares of Mineralys Therapeutics in the fourth quarter valued at approximately $285,000. Institutional investors own 84.46% of the company’s stock.

Insider Transactions at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $97,888.70. Following the transaction, the chief financial officer now directly owns 226,097 shares of the company’s stock, valued at approximately $2,057,482.70. The trade was a 4.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jon Congleton sold 18,333 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.06, for a total transaction of $166,096.98. Following the completion of the sale, the chief executive officer now owns 877,608 shares of the company’s stock, valued at approximately $7,951,128.48. The trade was a 2.05 % decrease in their position. The disclosure for this sale can be found here. 33.24% of the stock is currently owned by insiders.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock opened at $14.00 on Thursday. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.38. The firm’s 50 day simple moving average is $11.78 and its 200-day simple moving average is $12.26. The company has a market cap of $878.99 million, a P/E ratio of -3.85 and a beta of 1.50.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. On average, analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MLYS. HC Wainwright raised their target price on Mineralys Therapeutics from $30.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday. Guggenheim reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, The Goldman Sachs Group reduced their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, February 13th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.